Cogent Biosciences (COGT) Cash from Operations (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Cash from Operations data on file, last reported at 86883000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 30.63% year-over-year to 86883000.0 in Q1 2026; TTM through Mar 2026 was 284816000.0, a 28.43% decrease from a year earlier, with the FY2025 full-year figure at 264444000.0, down 27.26% from the prior year.
• Cash from Operations for Q1 2026 stood at 86883000.0, down from 79105000.0 in the prior quarter.
• Over the last five years, Cash from Operations for COGT reached as high as 26456000.0 in Q2 2022 and fell as low as 86883000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 48904705.88 across 5 years, with a median of 44070000.0 in 2023.
• Across the five-year window, Cash from Operations slumped 149.29% in 2022 and retreated 10.25% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 29408000.0 in 2022, then plunged by 49.86% to 44070000.0 in 2023, then tumbled by 37.46% to 60577000.0 in 2024, then slumped by 30.59% to 79105000.0 in 2025, then declined by 9.83% to 86883000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 86883000.0 in Q1 2026, 79105000.0 in Q4 2025, and 64286000.0 in Q3 2025.